Skip to main content

Table 3 Association between different duration of low-dose ASA use prior to end of follow-up identified by primary care data (UK Biobank) with all-cause and common subtype dementia incidence (= 136,589)

From: Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies

 

N total

Prevalence of CHD (%)

All-cause dementia

Alzheimer’s disease

Vascular dementia

ncase

OR (95% CI) a

ncase

OR (95% CI) a

ncase

OR (95% CI) a

Never-user

100,252

2.7

1427

Ref

521

Ref

318

Ref

User for ≤5 years prior to end of follow-up

2385

32.8

216

Excluded b

64

Excluded b

99

Excluded b

User for >5 to ≤10 years prior to end of follow-up

9752

36.1

309

0.95 (0.86, 1.05)

110

1.02 (0.86, 1.20)

92

0.87 (0.73, 1.03)

User for > 10 years prior to end of follow-up

24,200

36.8

595

0.51 (0.47, 0.56)

198

0.58 (0.51, 0.68)

197

0.48 (0.42, 0.56)

  1. Note: Statistically significant results are printed in bold
  2. aResults of multivariable logistic regression models, adjusted for covariates related to cardiovascular risk (all variables shown in Supplementary Table A3)
  3. bExcluded due to protopathic bias (see Discussion, Strengths and Limitations of this Study)